Eversept Partners LP Trims Stock Position in Bioventus Inc. $BVS

Eversept Partners LP decreased its stake in Bioventus Inc. (NASDAQ:BVS) by 66.2% during the first quarter, Holdings Channel reports. The institutional investor owned 159,110 shares of the company’s stock after selling 312,147 shares during the quarter. Eversept Partners LP’s holdings in Bioventus were worth $1,453,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also bought and sold shares of BVS. Nantahala Capital Management LLC increased its holdings in shares of Bioventus by 28.0% during the 2nd quarter. Nantahala Capital Management LLC now owns 5,280,842 shares of the company’s stock valued at $34,959,000 after purchasing an additional 1,155,192 shares in the last quarter. Hillsdale Investment Management Inc. increased its holdings in Bioventus by 148.7% in the first quarter. Hillsdale Investment Management Inc. now owns 671,139 shares of the company’s stock valued at $6,128,000 after buying an additional 401,230 shares in the last quarter. Essex Investment Management Co. LLC acquired a new position in shares of Bioventus in the fourth quarter worth about $2,886,000. Kent Lake PR LLC purchased a new stake in shares of Bioventus during the 2nd quarter worth about $2,317,000. Finally, Kennedy Capital Management LLC grew its position in shares of Bioventus by 219.6% during the 3rd quarter. Kennedy Capital Management LLC now owns 461,579 shares of the company’s stock valued at $3,088,000 after acquiring an additional 317,157 shares during the period. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bioventus in a report on Tuesday, June 2nd. Barrington Research reiterated an “outperform” rating and set a $14.00 target price on shares of Bioventus in a research report on Tuesday, June 30th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $15.00 price target on shares of Bioventus in a research note on Tuesday, June 16th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $14.75.

Bioventus Price Performance

NASDAQ:BVS opened at $12.45 on Tuesday. The stock has a 50 day moving average of $10.05 and a two-hundred day moving average of $9.33. Bioventus Inc. has a 12 month low of $5.81 and a 12 month high of $12.53. The firm has a market cap of $1.04 billion, a P/E ratio of 30.37, a price-to-earnings-growth ratio of 1.50 and a beta of 0.65. The company has a current ratio of 1.69, a quick ratio of 1.13 and a debt-to-equity ratio of 1.08.

Bioventus (NASDAQ:BVS) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.09 by $0.06. The firm had revenue of $132.09 million during the quarter. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, analysts expect that Bioventus Inc. will post 0.79 earnings per share for the current fiscal year.

Bioventus Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.